{"id":"NCT02873689","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients","officialTitle":"A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-27","primaryCompletion":"2018-03-14","completion":"2018-04-19","firstPosted":"2016-08-19","resultsPosted":"2019-07-05","lastUpdate":"2019-07-05"},"enrollment":217,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Heartburn","Gastroesophageal Reflux Disease"],"interventions":[{"type":"DRUG","name":"Dexlansoprazole","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dexlansoprazole 30 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the efficacy and safety of dexlansoprazole compared to placebo in relief of daytime and nighttime heartburn over 4 weeks in Chinese participants with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD).","primaryOutcome":{"measure":"Percentage of Days With Neither Daytime Nor Nighttime Heartburn During Treatment","timeFrame":"Up to Week 4","effectByArm":[{"arm":"Placebo","deltaMin":32.67,"sd":null},{"arm":"Dexlansoprazole 30 mg","deltaMin":51.72,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.057"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":25,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://general.takedapharm.com/content/file/pi.pdf?applicationcode=9efb34b3-fb69-4190-a2be-a90b8cb94e25&filetypecode=DEXILANTPI"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":108},"commonTop":["Upper respiratory tract infection","Nasopharyngitis"]}}